XML 73 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Sale of PerClot (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 23, 2023
Jul. 28, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of non-financial assets, net     $ 14,250 $ 0 $ 19,000
Gain from sale of non-financial assets     14,250 0 15,923
Total sources of revenue     354,004 313,789 $ 298,836
Sublease Income     278 $ 306  
PerClot          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets   $ 41,000      
Proceeds from sale of non-financial assets, net   25,000      
Derecognition of intangible assets   1,600      
Write off of prepaids   1,500      
Gain (loss) on disposition of business   15,900      
Gain from sale of non-financial assets     14,300    
Total sources of revenue     $ 5,100    
PerClot | Transfer Of PerClot Manufacturing Equipment          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration receivable   780      
PerClot | Starch Medical Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent liability payment $ 4,500        
PerClot | Artivion, Inc. And Starch Medical, Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets   54,500      
Proceeds from sale of non-financial assets, net $ 18,800 25,000      
PerClot | Artivion, Inc. And Starch Medical, Inc. | Baxter Achievement Of Worldwide Sales          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration receivable   10,000      
PerClot | Starch Medical Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets   13,500      
Proceeds from sale of non-financial assets, net   6,000      
PerClot | Starch Medical Inc. | Baxter Achievement Of Worldwide Sales          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration receivable   $ 3,000